Literature DB >> 2304382

The products of the mdr1a and mdr1b genes from multidrug resistant murine cells have similar degradation rates.

D Cohen1, C P Yang, S B Horwitz.   

Abstract

Two vinblastine-resistant sublines of the murine macrophage-like cell line J774.2, J7.V1-1 and J7.V3-1, overproduce unique forms of P-glycoprotein that are encoded by distinct mdr genes, mdr1b and mdr1a, respectively. Degradation rates of the two P-glycoprotein isoforms were measured by immunoprecipitation of P-glycoprotein. The half-life of immunoprecipitable P-glycoprotein from J7.V1-1 cells was 16.8 +/- 0.5 hours and from J7.V3-1 cells, 17.4 +/- 0.5 hours. This rate was not influenced by the presence of vinblastine in the growth medium. The data indicate that P-glycoproteins derived from distinct genes have similar degradation rates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2304382     DOI: 10.1016/0024-3205(90)90004-b

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  Molecular analysis of the multidrug transporter.

Authors:  U A Germann
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 2.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

Review 3.  Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.

Authors:  B T Hill
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs.

Authors:  Yong Tsuey Li; Ming Jang Chua; Anil Philip Kunnath; Ezharul Hoque Chowdhury
Journal:  Int J Nanomedicine       Date:  2012-06-05

5.  Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies.

Authors:  M A Barrand; P R Twentyman
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.